LIQUIDIA CORP (LQDA) Stock Fundamental Analysis

NASDAQ:LQDA • US53635D2027

33.59 USD
-1.46 (-4.17%)
At close: Feb 20, 2026
33.7 USD
+0.11 (+0.33%)
After Hours: 2/20/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall LQDA gets a fundamental rating of 3 out of 10. We evaluated LQDA against 192 industry peers in the Pharmaceuticals industry. LQDA has a bad profitability rating. Also its financial health evaluation is rather negative. LQDA is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year LQDA has reported negative net income.
  • In the past year LQDA has reported a negative cash flow from operations.
  • In the past 5 years LQDA always reported negative net income.
  • In the past 5 years LQDA always reported negative operating cash flow.
LQDA Yearly Net Income VS EBIT VS OCF VS FCFLQDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • The Return On Assets of LQDA (-44.15%) is comparable to the rest of the industry.
  • With a Return On Equity value of -552.55%, LQDA is not doing good in the industry: 80.73% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -44.15%
ROE -552.55%
ROIC N/A
ROA(3y)-51.66%
ROA(5y)-50.39%
ROE(3y)-127.25%
ROE(5y)-103.75%
ROIC(3y)N/A
ROIC(5y)N/A
LQDA Yearly ROA, ROE, ROICLQDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200

1.3 Margins

  • With an excellent Gross Margin value of 89.11%, LQDA belongs to the best of the industry, outperforming 91.67% of the companies in the same industry.
  • In the last couple of years the Gross Margin of LQDA has declined.
  • LQDA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 89.11%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.82%
GM growth 5Y-8.41%
LQDA Yearly Profit, Operating, Gross MarginsLQDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • LQDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, LQDA has more shares outstanding
  • LQDA has more shares outstanding than it did 5 years ago.
  • LQDA has a worse debt/assets ratio than last year.
LQDA Yearly Shares OutstandingLQDA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
LQDA Yearly Total Debt VS Total AssetsLQDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • An Altman-Z score of 3.16 indicates that LQDA is not in any danger for bankruptcy at the moment.
  • LQDA has a better Altman-Z score (3.16) than 68.75% of its industry peers.
  • LQDA has a Debt/Equity ratio of 6.19. This is a high value indicating a heavy dependency on external financing.
  • The Debt to Equity ratio of LQDA (6.19) is worse than 81.77% of its industry peers.
Industry RankSector Rank
Debt/Equity 6.19
Debt/FCF N/A
Altman-Z 3.16
ROIC/WACCN/A
WACC9.24%
LQDA Yearly LT Debt VS Equity VS FCFLQDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

2.3 Liquidity

  • LQDA has a Current Ratio of 2.20. This indicates that LQDA is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of LQDA (2.20) is comparable to the rest of the industry.
  • LQDA has a Quick Ratio of 1.96. This is a normal value and indicates that LQDA is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of LQDA (1.96) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.2
Quick Ratio 1.96
LQDA Yearly Current Assets VS Current LiabilitesLQDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 11.66% over the past year.
  • LQDA shows a strong growth in Revenue. In the last year, the Revenue has grown by 343.41%.
  • The Revenue has been growing by 11.64% on average over the past years. This is quite good.
EPS 1Y (TTM)11.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.67%
Revenue 1Y (TTM)343.41%
Revenue growth 3Y2.89%
Revenue growth 5Y11.64%
Sales Q2Q%1121.72%

3.2 Future

  • The Earnings Per Share is expected to grow by 40.12% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 125.31% on average over the next years. This is a very strong growth
EPS Next Y53.49%
EPS Next 2Y76.86%
EPS Next 3Y54.56%
EPS Next 5Y40.12%
Revenue Next Year844.45%
Revenue Next 2Y449.01%
Revenue Next 3Y237.41%
Revenue Next 5Y125.31%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
LQDA Yearly Revenue VS EstimatesLQDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B
LQDA Yearly EPS VS EstimatesLQDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • LQDA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • The Price/Forward Earnings ratio is 17.83, which indicates a rather expensive current valuation of LQDA.
  • Based on the Price/Forward Earnings ratio, LQDA is valued cheaply inside the industry as 80.73% of the companies are valued more expensively.
  • LQDA's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 28.02.
Industry RankSector Rank
PE N/A
Fwd PE 17.83
LQDA Price Earnings VS Forward Price EarningsLQDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LQDA Per share dataLQDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • LQDA's earnings are expected to grow with 54.56% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y76.86%
EPS Next 3Y54.56%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • LQDA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LIQUIDIA CORP

NASDAQ:LQDA (2/20/2026, 8:00:01 PM)

After market: 33.7 +0.11 (+0.33%)

33.59

-1.46 (-4.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-03
Earnings (Next)03-12
Inst Owners72.57%
Inst Owner Change-6.33%
Ins Owners3.84%
Ins Owner Change1.19%
Market Cap2.92B
Revenue(TTM)69.22M
Net Income(TTM)-121.85M
Analysts82.67
Price Target46.58 (38.67%)
Short Float %17.29%
Short Ratio7.7
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)39.4%
Min EPS beat(2)-11.43%
Max EPS beat(2)90.23%
EPS beat(4)1
Avg EPS beat(4)11.84%
Min EPS beat(4)-20.44%
Max EPS beat(4)90.23%
EPS beat(8)2
Avg EPS beat(8)-9.9%
EPS beat(12)3
Avg EPS beat(12)-14.24%
EPS beat(16)5
Avg EPS beat(16)-16.1%
Revenue beat(2)2
Avg Revenue beat(2)148.62%
Min Revenue beat(2)114.23%
Max Revenue beat(2)183%
Revenue beat(4)2
Avg Revenue beat(4)63.27%
Min Revenue beat(4)-37.8%
Max Revenue beat(4)183%
Revenue beat(8)3
Avg Revenue beat(8)19.43%
Revenue beat(12)6
Avg Revenue beat(12)17%
Revenue beat(16)9
Avg Revenue beat(16)12.88%
PT rev (1m)2.49%
PT rev (3m)5.38%
EPS NQ rev (1m)0%
EPS NQ rev (3m)9094.5%
EPS NY rev (1m)0%
EPS NY rev (3m)52.13%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)29.89%
Revenue NY rev (1m)0%
Revenue NY rev (3m)108.53%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 17.83
P/S 42.22
P/FCF N/A
P/OCF N/A
P/B 132.52
P/tB 192.75
EV/EBITDA N/A
EPS(TTM)-1.44
EYN/A
EPS(NY)1.88
Fwd EY5.61%
FCF(TTM)-1.24
FCFYN/A
OCF(TTM)-1.16
OCFYN/A
SpS0.8
BVpS0.25
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -44.15%
ROE -552.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 89.11%
FCFM N/A
ROA(3y)-51.66%
ROA(5y)-50.39%
ROE(3y)-127.25%
ROE(5y)-103.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.82%
GM growth 5Y-8.41%
F-Score4
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 6.19
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 410.55%
Cap/Sales 10.24%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.2
Quick Ratio 1.96
Altman-Z 3.16
F-Score4
WACC9.24%
ROIC/WACCN/A
Cap/Depr(3y)306.37%
Cap/Depr(5y)189%
Cap/Sales(3y)42.88%
Cap/Sales(5y)46.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.67%
EPS Next Y53.49%
EPS Next 2Y76.86%
EPS Next 3Y54.56%
EPS Next 5Y40.12%
Revenue 1Y (TTM)343.41%
Revenue growth 3Y2.89%
Revenue growth 5Y11.64%
Sales Q2Q%1121.72%
Revenue Next Year844.45%
Revenue Next 2Y449.01%
Revenue Next 3Y237.41%
Revenue Next 5Y125.31%
EBIT growth 1Y3.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year53.84%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-158.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-233.81%
OCF growth 3YN/A
OCF growth 5YN/A

LIQUIDIA CORP / LQDA FAQ

What is the ChartMill fundamental rating of LIQUIDIA CORP (LQDA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to LQDA.


What is the valuation status of LIQUIDIA CORP (LQDA) stock?

ChartMill assigns a valuation rating of 3 / 10 to LIQUIDIA CORP (LQDA). This can be considered as Overvalued.


What is the profitability of LQDA stock?

LIQUIDIA CORP (LQDA) has a profitability rating of 1 / 10.


What is the financial health of LIQUIDIA CORP (LQDA) stock?

The financial health rating of LIQUIDIA CORP (LQDA) is 3 / 10.